Cargando…
Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin
Inhibition of dipeptidyl peptidase-4 (DPP-4) as a novel therapy for type 2 diabetes is based on prevention of the inactivation process of bioactive peptides, the most important in the context of treatment of diabetes of which is glucagon-like peptide-1(GLP-1). Most clinical experience with DPP-4 inh...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2496991/ https://www.ncbi.nlm.nih.gov/pubmed/18561513 |
_version_ | 1782158280580136960 |
---|---|
author | Ahrén, Bo |
author_facet | Ahrén, Bo |
author_sort | Ahrén, Bo |
collection | PubMed |
description | Inhibition of dipeptidyl peptidase-4 (DPP-4) as a novel therapy for type 2 diabetes is based on prevention of the inactivation process of bioactive peptides, the most important in the context of treatment of diabetes of which is glucagon-like peptide-1(GLP-1). Most clinical experience with DPP-4 inhibition is based on vildagliptin (Galvus(R), Novartis) and sitagliptin (Januvia(R), Merck). These compounds improve glycemic control both in monotherapy and in combination with other oral hyperglycemic agents. Both have also been shown to efficiently improve glycemic control when added to ongoing metformin therapy in patients with inadequate glycemic control. Under that condition, they reduce HbA(1c) levels by 0.65%–1.1% (baseline HbA(1c) 7.2–8.7%) in studies up to 52 weeks of duration in combination versus continuous therapy with metformin alone. Sitagliptin has also been examined in initial combination therapy with metformin have; HbA(1c) was reduced by this combination by 2.1% (baseline HbA(1c) 8.8%) after 24 weeks of treatment. Both fasting and prandial glucose are reduced by DPP-4 inhibition in combination with metformin in association with improvement of insulin secretion and insulin resistance and increase in concentrations of active GLP-1. The combination of DPP-4 inhibition and metformin has been shown to be highly tolerable with very low risk of hypoglycemia. Hence, DPP-4 inhibition in combination with metformin is an efficient, safland tolerable combination therapy for type 2 diabetes. |
format | Text |
id | pubmed-2496991 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-24969912008-08-26 Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin Ahrén, Bo Vasc Health Risk Manag Review Inhibition of dipeptidyl peptidase-4 (DPP-4) as a novel therapy for type 2 diabetes is based on prevention of the inactivation process of bioactive peptides, the most important in the context of treatment of diabetes of which is glucagon-like peptide-1(GLP-1). Most clinical experience with DPP-4 inhibition is based on vildagliptin (Galvus(R), Novartis) and sitagliptin (Januvia(R), Merck). These compounds improve glycemic control both in monotherapy and in combination with other oral hyperglycemic agents. Both have also been shown to efficiently improve glycemic control when added to ongoing metformin therapy in patients with inadequate glycemic control. Under that condition, they reduce HbA(1c) levels by 0.65%–1.1% (baseline HbA(1c) 7.2–8.7%) in studies up to 52 weeks of duration in combination versus continuous therapy with metformin alone. Sitagliptin has also been examined in initial combination therapy with metformin have; HbA(1c) was reduced by this combination by 2.1% (baseline HbA(1c) 8.8%) after 24 weeks of treatment. Both fasting and prandial glucose are reduced by DPP-4 inhibition in combination with metformin in association with improvement of insulin secretion and insulin resistance and increase in concentrations of active GLP-1. The combination of DPP-4 inhibition and metformin has been shown to be highly tolerable with very low risk of hypoglycemia. Hence, DPP-4 inhibition in combination with metformin is an efficient, safland tolerable combination therapy for type 2 diabetes. Dove Medical Press 2008-04 2008-04 /pmc/articles/PMC2496991/ /pubmed/18561513 Text en © 2008 Dove Medical Press Limited. All rights reserved |
spellingShingle | Review Ahrén, Bo Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin |
title | Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin |
title_full | Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin |
title_fullStr | Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin |
title_full_unstemmed | Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin |
title_short | Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin |
title_sort | novel combination treatment of type 2 diabetes dpp-4 inhibition + metformin |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2496991/ https://www.ncbi.nlm.nih.gov/pubmed/18561513 |
work_keys_str_mv | AT ahrenbo novelcombinationtreatmentoftype2diabetesdpp4inhibitionmetformin |